The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, March 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#45 of 1,259)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 15 news stories from 15 outlets.

New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the…

(GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and…

The ability to measure synapse damage or loss would facilitate diagnosis of a broad range of neurological diseases and the…

(GLOBE NEWSWIRE) -- Cognition Therapeutics Inc., a clinical-stage neuroscience company focused on the protection and…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 11 additional news stories.